Temsirolimus

CHEMBL1201182 Phase 4 Одобрено Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1030.3 g/mol

LogP

5.6

Phase

4

This targeted cancer therapy is given intravenously to treat advanced renal cell carcinoma (kidney cancer). It works by blocking a protein called mTOR, which signals cancer cells to grow and multiply. It is also being investigated for use in other cancers.

Молекулярная масса

1030,3000 g/mol

LogP

5,60

TPSA

242,00 Å²

Правило пяти Липинского

Не соответствует

Терапевтические области

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Age-Related Macular Degeneration Respiratory Disease Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Gout HIV/AIDS Hepatitis C Heart Failure Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure

Embed this structure

SMILES

CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C

InChI

InChI=1S/C56H87NO16/c1-33-17-13-12-14-18-34(2)45(68-9)29-41-22-20-39(7)56(67,73-41)51(63)52(64)57-24-16-15-19-42(57)53(65)71-46(30-43(60)35(3)26-38(6)49(62)50(70-11)48(61)37(5)25-33)36(4)27-40-21-23-44(47(28-40)69-10)72-54(66)55(8,31-58)32-59/h12-14,17-18,26,33,35-37,39-42,44-47,49-50,58-59,62,67H,15-16,19-25,27-32H2,1-11H3/b14-12+,17-13+,34-18+,38-26+/t33-,35-,36-,37-,39-,40+,41+,42+,44-,45+,46+,47-,49-,50+,56-/m1/s1

Molecular Formula

C56H87NO16

HBD / HBA

4 / 16

Вращаемые Связи

11

Тяжёлые Атомы

73

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

This targeted cancer therapy is given intravenously to treat advanced renal cell carcinoma (kidney cancer). It works by blocking a protein called mTOR, which signals cancer cells to grow and multiply. It is also being investigated for use in other cancers.

Yes, Temsirolimus is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201182. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918289. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Ищете информацию, доступную для пациентов?

Temsirolimus на PillFYI

Структура

Краткие Данные

Формула: C56H87NO16
Синонимы: 1

Внешние ссылки

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.